Literature DB >> 3048457

Diagnosis and treatment of Zollinger-Ellison syndrome.

M Mignon, S Bonfils.   

Abstract

A diagnostic and therapeutic strategy for the management of patients with Zollinger-Ellison syndrome has been developed, based on the review of a large personal experience and the most recent literature. The mainstay of a modern ZES management is the eradication of tumoral processes whenever feasible. Diagnosis is centred upon gastric acid and gastrin secretion measurements both in basal conditions and on secretin stimulation. Recognition of other endocrine involvement and familial inheritance is of the utmost importance in distinguishing sporadic ZES patients from those who have the condition known as multiple endocrine neoplasia type I. Blood calcium and phosphorus levels, parathyroid hormone concentration, combined if necessary with urinary cyclic AMP excretion measurement, should be performed routinely once ZES diagnosis is established or highly suspected. Localization of the tumour is the next essential step, and this has been considerably facilitated by the recent development in imaging techniques: it involves computerized axial tomography and selective abdominal angiography, a combination of which allows tumour detection in 60-70% of sporadic gastrinoma patients, with a maximal sensitivity for well-developed hepatic metastases. In sporadic ZES exploratory laparotomy is legitimate when preoperative localization of the tumour has failed; this laparotomy will allow further detection and then eradication of gastrinomas in a significant number of patients. Control of gastric acid secretion is mandatory throughout the work-up period; modern antisecretory agents are efficacious in most cases; total gastrectomy, when control of acid hypersecretion has failed, is now exceptional. Eradication of the tumour should be attempted in cases of sporadic ZES in the absence of recognizable liver involvement. The chance of a definite cure provided by surgery when performed by an experienced surgeon varies from 20% to 60% in pancreatic and ectopic gastrinomas respectively. In ZES patients with MEN I, exploratory laparotomy is seldom indicated (other than for symptomatic associated endocrine secretion), as the chance of a definite cure by surgery is very rare. Parathyroid surgery is often indicated and should take place before any form of abdominal surgery. In cases of hepatic metastases, chemotherapy with streptozocin and fluorouracil is indicated and soon, perhaps, chemo-embolization.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3048457     DOI: 10.1016/s0950-3528(88)80013-7

Source DB:  PubMed          Journal:  Baillieres Clin Gastroenterol        ISSN: 0950-3528


  13 in total

1.  Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE).

Authors:  G Cadiot; G Bonnaud; R Lebtahi; L Sarda; P Ruszniewski; D Le Guludec; M Mignon
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

2.  Prognostic factors in patients with endocrine tumours of the duodenopancreatic area.

Authors:  I Madeira; B Terris; M Voss; A Denys; A Sauvanet; J F Flejou; V Vilgrain; J Belghiti; P Bernades; P Ruszniewski
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

3.  Duodenal ulcers that are difficult to heal.

Authors:  R Pounder
Journal:  BMJ       Date:  1988-12-17

4.  Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia.

Authors:  M Renga; G Brandi; G M Paganelli; C Calabrese; S Papa; A Tosti; P Tomassetti; M Miglioli; G Biasco
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

5.  Oral calcium tolerance test in the early diagnosis of primary hyperparathyroidism and multiple endocrine neoplasia type 1 in patients with the Zollinger-Ellison syndrome. Groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison.

Authors:  G Cadiot; P Houillier; A Allouch; M Paillard; M Mignon
Journal:  Gut       Date:  1996-08       Impact factor: 23.059

6.  Gastric endocrine cell evolution in patients with Zollinger-Ellison syndrome. Influence of gastrinoma growth and long-term omeprazole treatment.

Authors:  G Cadiot; T Lehy; P Ruszniewski; S Bonfils; M Mignon
Journal:  Dig Dis Sci       Date:  1993-07       Impact factor: 3.199

Review 7.  Current approach to the management of gastrinoma and insulinoma in adults with multiple endocrine neoplasia type I.

Authors:  M Mignon; P Ruszniewski; P Podevin; L Sabbagh; G Cadiot; D Rigaud; S Bonfils
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

8.  Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome.

Authors:  T Lehy; G Cadiot; M Mignon; P Ruszniewski; S Bonfils
Journal:  Gut       Date:  1992-09       Impact factor: 23.059

9.  Gastrinomas: a 42-year experience.

Authors:  E L Kaplan; K Horvath; A Udekwu; F Straus; C Schark; D J Ferguson; D B Skinner
Journal:  World J Surg       Date:  1990 May-Jun       Impact factor: 3.352

10.  Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. GRESZE: Groupe d'Etude du Syndrome de Zollinger-Ellison.

Authors:  E de Kerviler; G Cadiot; R Lebtahi; M Faraggi; D Le Guludec; M Mignon
Journal:  Eur J Nucl Med       Date:  1994-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.